LMR Partners’s Marker Therapeutics MRKR Stock Holding History

LMR Partners’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,439	Closed	-$40K	–	1124
2021 Q2	$40K	Buy	+1,439	New	+$37.9K	﹤0.01%	1021

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

LMR Partners's MRKR Position: Q3 2021 in Review

LMR Partners sold out of Marker Therapeutics (MRKR) in Q3 2021, closing a stake of 1,439 shares — an estimated $40K sold.

LMR Partners first reported a position in MRKR in Q2 2021 and held it in 1 quarter. The position peaked at $40K in Q2 2021. 63 funds tracked by Wall St. Rank hold MRKR as of Q3 2021.

LMR Partners reported no remaining Marker Therapeutics position as of Q3 2021 after selling out during the quarter.
LMR Partners sold 1,439 Marker Therapeutics shares in Q3 2021, an estimated $40K.
LMR Partners first reported a position in Marker Therapeutics in Q2 2021 and held it in 1 quarter.
LMR Partners's Marker Therapeutics position peaked at $40K in Q2 2021.
63 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2021.

Based on LMR Partners's 13F filing for Q3 2021, filed 15 Nov 2021.